CULLINAN THERAPEUTICS INC. - COMMON STOCK

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

14 11 2024 10:01:00 提供 Nasdaq GlobeNewswire

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

07 11 2024 07:00:01 提供 Nasdaq GlobeNewswire

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

05 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

04 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

16 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

17 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus

16 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

14 9 2024 04:15:00 提供 Nasdaq GlobeNewswire

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

28 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

08 8 2024 07:00:01 提供 Nasdaq GlobeNewswire

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

01 6 2024 07:00:00 提供 Nasdaq GlobeNewswire

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

24 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

23 5 2024 17:04:38 提供 Nasdaq GlobeNewswire

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

15 5 2024 16:05:00 提供 Nasdaq GlobeNewswire

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

29 4 2024 07:00:00 提供 Nasdaq GlobeNewswire

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

24 4 2024 10:09:18 提供 Nasdaq GlobeNewswire

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

16 4 2024 07:00:00 提供 Nasdaq GlobeNewswire

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

16 4 2024 06:59:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

14 3 2024 07:00:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

01 3 2024 07:00:00 提供 Nasdaq GlobeNewswire